Department of Clinical Biochemistry and Diagnostic Endocrinology, Mater Misericordiae University Hospital, Dublin, Republic of Ireland.
Ann Clin Biochem. 2014 Mar;51(Pt 2):258-68. doi: 10.1177/0004563213494078. Epub 2013 Sep 18.
Non-cardiac surgery is associated with major vascular complications and higher incidences of elevated plasma troponin (cTn) concentration. Goal-directed therapy (GDT) is a stroke volume (SV)-guided approach to intravenous (IV) fluid therapy that improves tissue perfusion, oxygenation and reduces post-operative complications. In patients undergoing major gastro-intestinal surgery, we compared high sensitive and contemporary troponin assays and correlated results with patient outcome.
Patients (n = 135) were randomized to receive IV fluid, guided by either the central venous pressure (CVP group, n = 45) or SV (± dopexamine inotrope, n = 45 per group). Serum was obtained pre- and post-operatively (0, 8 and 24 h) for troponin analysis by a prototype hs-cTnI assay (Abbott Laboratories), hs-cTnT (Roche Diagnostics) and contemporary cTnI (Beckman Coulter) assays.
All troponin measurements were increased (P ≤ 0.05) post-operatively but there was no difference (P > 0.05) amongst treatments. Post-operative increases were reported more frequently (P ≤ 0.05) and earlier with hs-cTnI. Temporal increases (P ≤ 0.05) were reported in patients with and without complications for hs-cTnI/T assays but only in the complications group for cTnI measurements. Elevations ≥99th centile occurred most often (P ≤ 0.05) for hs-cTnT measurements but with similar frequency for both outcome groups (all assays). Only the hs-cTnI assay showed an increased relative risk of mortality (P ≤ 0.05) for elevations ≥99th centile
Our study may suggest a possible preference for the hs-cTnI assay in the peri-operative setting; however, our findings should be verified for larger cohort studies where emerging reference range data is incorporated for improving risk prediction with hs-cTn assays.
非心脏手术与主要血管并发症和更高的血浆肌钙蛋白(cTn)浓度升高有关。目标导向治疗(GDT)是一种基于每搏量(SV)的静脉(IV)液体治疗方法,可改善组织灌注、氧合并减少术后并发症。在接受重大胃肠手术的患者中,我们比较了高敏和当代肌钙蛋白检测,并将结果与患者预后相关联。
患者(n=135)随机分为接受 IV 液体治疗,分别通过中心静脉压(CVP 组,n=45)或 SV(±多巴酚丁胺正性肌力药,每组 n=45)进行指导。在术前(0 小时)和术后(8 小时和 24 小时)采集血清,用于通过原型高敏 cTnI 检测(雅培实验室)、高敏 cTnT(罗氏诊断)和当代 cTnI(贝克曼库尔特)检测进行肌钙蛋白分析。
所有肌钙蛋白测量均在术后升高(P≤0.05),但治疗之间无差异(P>0.05)。hs-cTnI 报告的术后增加更频繁(P≤0.05)和更早。hs-cTnI/T 检测在有和无并发症的患者中均报告了时间性增加(P≤0.05),但仅在并发症组中报告了 cTnI 测量。hs-cTnT 测量的 99 百分位上限以上的升高最常见(P≤0.05),但在所有检测中,两组的发生率相似。只有 hs-cTnI 检测显示出 99 百分位上限以上升高的死亡率相对风险增加(P≤0.05)
我们的研究可能表明在围手术期环境中可能更倾向于使用 hs-cTnI 检测;然而,我们的发现应在更大的队列研究中得到验证,其中纳入新兴参考范围数据可提高 hs-cTn 检测的风险预测。